MedTrace Logo

Protein Intake and Exercise-induced Muscle Damage

NCT06235476 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2025-11-17

No results posted yet for this study

Summary

The goal of this clinical trial is to test the effect of different protein-enhancement strategies versus carbohydrate control on exercise-induced muscle damage in physically active older adults. The main question it aims to answer is:

What is the effect of three different protein-enhancement strategies (whey protein (WP), mixed plant-based protein (MPP), and use of protein-rich food products (PFP) on exercise-induced muscle damage in older adults compared to isocaloric carbohydrate control?

Participants will:

* Use a protein-enhancement strategy (WP, MPP or PFP) or carbohydrate control for a total of 5 weeks;
* Participate in a single walking bound (30/40/50 km) two weeks after the start of the study;
* Participate in a consecutive walking bound (4 days of 30/40/50 km) in the last week of the study period;
* Complete different questionnaires and give blood samples to test for muscle damage.

Conditions

Interventions

DIETARY_SUPPLEMENT

whey protein supplement

Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.

DIETARY_SUPPLEMENT

mixed plant-based protein supplement

Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.

OTHER

e-health application

Daily use of an e-health application with dietary intake counselling to increase protein intake. The overall goal of these advices is to increase protein intake from \<1.0g/kg/bw/d to \>1.2g/kg/bw/d which is approximately 30 grams of additional protein per day (similar to the other arms of the intervention).

DIETARY_SUPPLEMENT

isocaloric carbohydrate control

Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.

Sponsors & Collaborators

  • Cosun

    collaborator UNKNOWN

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Maria Hopman, prof. dr. · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-10
Primary Completion
2024-07-19
Completion
2025-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06235476 on ClinicalTrials.gov